Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-06-24

Clinical Trial Update: Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib plus protracted temozolomide in recurrent glioblastoma completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nexavar (Sorafenib)
  • Temodar (Temozolomide)

Snippet

Sponsor: Duke University | Conditions: Recurrent Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2013-06-24